Lead-up to Novo Nordisk report: Growth-heavy quarter with GLP-1 focus ahead

Thursday's quarterly report from Novo Nordisk will emphasize the pharmaceutical company's diabetes 2 treatments Ozempic and Rybelsus, as well the new weight-loss drug Wegovy, which is in high demand.
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk is looking into a growth-heavy Q2, as it has had tailwind with diabetes 2 drugs Ozempic and Rybelsus, and as the demand is high for its new weight-loss treatment Wegovy.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading